Postoperative gnrh analog treatment for the prevention of recurrences of uterine myomas after myomectomy: A pilot study

Gynecologic and Obstetric Investigation

Volumn 43, Issue 4, 1997, Pages 251-254

  Varalà, Vincenzo ^a   Lanzone, Antonio ^b   Monaco, Antonino ^a   Scribanti, Andrea ^a   Guida, Costabile ^c   Mancuso, Salvatore ^c  

^a Ospedale di Biella   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

GnRH analog; Myomectomy; Pharmacologic treatment of fibroids; Uterine leiomyomata

Indexed keywords

GONADORELIN DERIVATIVE; LEUPRORELIN;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR RECURRENCE; UTERUS; UTERUS MYOMA;

ADULT; DELAYED-ACTION PREPARATIONS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; LEIOMYOMA; LEUPROLIDE; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; POSTOPERATIVE CARE; UTERINE NEOPLASMS; UTERUS;

EID: 0031001880     PISSN: 03787346     EISSN: 1423002X     Source Type: Journal    
DOI: 10.1159/000291867     Document Type: Article

References (27)

1. Buttram VC Jr, Reiter RC: Uterine leiomyomata: Etiology, symptomatology and management. Ferii Steril 1981,36:433-445.
2. Williams IA, Shaw RW: Effect of nafarelin on uterine fibrosis measured by ultrasound and magnetic resonance imaging. Eur J Obstet Gynecol 1990;34:111-117.
3. Franssen AMHW, Willemscn WNP, Corbcy RS, Docsburg WH, van’t Veen AJ, Rolland R: Subcutaneous injection or infusion of gonadotropin releasing-hormone agonist buserelin in the treatment of enlarged uteri harboring lio-myomata. Eur J Obstet Gynecol Reprod Biol 1991;40:221-228.
4. Costantini S. Anserini P, Valenzano M, Re-morgida V, Venturini PL, De Cecco L: Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: Analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot. Eur J Obstet Gynecol Reprod Bio 1990;37:63-69.
5. Letterie GS, Coddington CC, Winkel CA, Shawker TH, Loriaux DL, Collins RL: Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: Longterm follow-up. Fertil Steril 1989;51:951-956.
6. Matta WH, Shaw RW, Nyc M: Long-term follow-up of patients with uterine fibroids after treatment with the LHRI1 agonist buserclin. Br J Obstet Gynaecol 1989;96:200-206.
7. West CP, Lumsden MA. Lawson S, Williamson J, Baird DT: Shrinkage of uterine fibroids during therapy with goserclin (Zoladex): A luteinizing hormone releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987;48:45-51.
8. Fedele L, Vercellini P, Bianchi S, Brioschi D, Dorta M: Treatment with GnRH agonists before myomectomy and the risk of short-term myoma recurrence. Br J Obstet Gynaecol 1990; 97:393-396.
9. Goldzieher JW, Maqueo M. Ricaud L. Aguilar JA, Canales E: Induction of degenerative changes in uterine myomas by high-dose progestin therapy. Am J Obstet Gynecol 1966:96: 1078-1087.
10. Wilson EA, Yang F, Rees ED: Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue. Obstet Gynecol 1980;55:20-24.
11. Pollow K, Geilfuss J, Boquoi E, Pollow B: Estrogen and progesterone binding proteins in normal human myometrium and leiomyoma tissue. J Clin Chem Clin Biochem 1978:16: 503-511.
12. Maheux R, Lemay A, Merct P: The use of intranasal hormone releasing hormone agonist in uterine leiomyomas. Fertil Steril 1987;47:229-233.
13. Healy DL, Lawson SR, Abbott M. Baird DT, Frazer HM: Toward removing uterine fibroids without surgery: Subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase. J Clin Endocrinol Metab 1986;63:619-625.
14. Filicori M. Hall DA. Loughlin JS, Rivier J. Vale W, Crowley WF Jr: A conservative approach to the management of uterine leiomyoma: Pituitary desensitization by a luteinizing hormone-releasing hormone analogue. Am J Obstet Gynecol 1983;147:726-727.
15. Perl V, Marquez J, Schally AV, Comaru-Schal-ly AM, Leal G, Zacharias S, Gomcz-Lira C: Treatment of leiomyomata uteri with Ö-Trp6-luteinizing hormone-releasing hormone. Fertil Steril 1987;48:383-389.
16. Friedmann AJ, Harrison-Atlas D, Barbiéri RL, Benacerraf BR, Gleason R, Schiff I: A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril 1989;51:251-256.
17. Benagiano G, Morini A, Aleandri V, Piccinno F, Primiero FM, Abbondante G, Elkind-Hirsch K: Sequential GnRH superagonist and medroxyprogesterone acetate treatment of uterine leiomyomata. Int J Obstet Gynecol 1990;33: 333-343.
18. Friedman AJ, Delay M. Joneau-Nocross M. Fine C, Rein MS: Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. Fertil Steril 1992;58:205-208.
19. Rico H, Arnanaz F, Revilla M. Pcrcra S, Iritia M, Villa LF. Arribas I: Total and regional bone mineral content in women treated with GnRH agonists. Calcif Tissue Int 1992;52:354-357.
20. Waibel-Trebcr S. Minnc HW, Scharia SH. Bre-man TH. Ziegler R. Leyendeker G: Reversible bone loss in women treated with GnRH-antag-onist for endometriosis and uterine leiomyoma. Hum Reprod 1984;4:384-348.
21. Matta WH, Shaw RW, Heps R, Evans R: Reversible trabecular bone density loss following induced hypo-cstrogcnism with GnRH analogue buserel in in premenopausal women. Clin Endocrinol 1988:29:45-51.
22. Johansen JS, Riis BJ. Hassagcr C, Moen M, Jacobson J, Christiansen C: The effects of a gonacotropin-relcasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988;67:701-706.
23. Dawcod MY, Lewis V, Ramos J: Cortical and trabecular bone mineral content in women with endometriosis: Effect of gonadotropinreleasing hormone agonist and danazol. Fertil Steril 1989;52:21-26.
24. Stevenson JC. Lees B. Gardner R. Shaw RW: A comparison of the skeletal effect of goserclin and danazol in premenopausal women with endometriosis. Horm Res 1989:32:161-163.
25. Whitehouse RM. Adams JE, Baucroff K, Vaughan-Williams CA, Elstein M: The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis. Clin Endocrinol 1990:33:365-373.
26. Dodin S. Lemay A. Maheux R. Dumont M. Turcot-Lemay L: Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 1991;77:410-415.
27. Nencioni T, Penotti M. Barbieri-Carones M, Ortolain S, Trenisan C, Polvani S: Gonadotropin releasing hormone agonist therapy and its effect on bone mass. Gynecol Endocrinol 1991: 5:49-56.